Medulloblastoma: Causes, Symptoms, Diagnosis, Treatment, and Prognosis

Medulloblastoma is a rare but aggressive type of brain cancer that primarily affects children, although it can also occur in adults. Originating in the cerebellum—the part of the brain responsible for balance and coordination—medulloblastoma is classified as a high-grade (WHO Grade IV) malignant tumor. Despite its aggressive nature, advances in early diagnosis, molecular classification, and modern treatment approaches have significantly improved survival rates over the past few decades.

This comprehensive guide explores everything you need to know about medulloblastoma, including its causes, symptoms, types, diagnosis, treatment options, prognosis, and ongoing research.

~What Is Medulloblastoma?

Medulloblastoma is an embryonal tumor of the central nervous system (CNS) that develops from primitive nerve cells in the cerebellum. It tends to grow rapidly and can spread (metastasize) through the cerebrospinal fluid (CSF) to other areas of the brain and spinal cord.

Medulloblastoma accounts for:

• Around 15–20% of all pediatric brain tumors

• Less than 1% of adult brain tumors

It is most commonly diagnosed in children between 3 and 8 years of age, with a smaller peak in adolescence.

~Causes and Risk Factors of Medulloblastoma

What Causes Medulloblastoma?

The exact cause of medulloblastoma remains unknown. However, researchers believe it results from genetic mutations that disrupt normal brain cell development and division during early life.

Unlike many adult cancers, medulloblastoma is not strongly linked to environmental factors such as radiation exposure or lifestyle habits.

Known Risk Factors

Although rare, certain genetic conditions increase the risk of developing medulloblastoma, including:

• Gorlin syndrome (Nevoid Basal Cell Carcinoma Syndrome)

• Turcot syndrome

• Li-Fraumeni syndrome

• Familial adenomatous polyposis (FAP)

Most children diagnosed with medulloblastoma do not have an inherited genetic disorder, meaning the disease often occurs sporadically.

~Types of Medulloblastoma (Molecular Subgroups)

Modern medicine classifies medulloblastoma into four main molecular subgroups, which are crucial for determining prognosis and treatment strategies.

1. WNT-Activated Medulloblastoma

• Best overall prognosis

• Accounts for about 10% of cases

• Rarely spreads

• High survival rates (over 90%)

2. SHH-Activated Medulloblastoma

• Common in infants and adults

• Prognosis varies depending on genetic features

• Linked to mutations in the Sonic Hedgehog pathway

3. Group 3 Medulloblastoma

• More aggressive

• Higher risk of metastasis

• Often diagnosed in young children

• Lower survival rates compared to WNT and SHH groups

4. Group 4 Medulloblastoma

• Most common subtype

• Intermediate prognosis

• More frequent in males

Understanding the molecular subtype allows doctors to personalize treatment, reducing side effects while improving outcomes.

~Symptoms of Medulloblastoma

Symptoms of medulloblastoma often develop quickly due to rapid tumor growth and increased pressure inside the skull (intracranial pressure).

Common Symptoms

• Persistent headaches, especially in the morning

• Nausea and vomiting

• Balance problems and clumsiness

• Difficulty walking (ataxia)

• Vision problems, including double vision

• Fatigue and irritability

Symptoms in Infants

• Enlarged head size (hydrocephalus)

• Bulging fontanelle (soft spot)

• Poor feeding

• Developmental delays

Because these symptoms can mimic less serious conditions, early diagnosis may be challenging.

~How Is Medulloblastoma Diagnosed?

Neurological Examination

Doctors begin with a detailed neurological exam to assess coordination, reflexes, vision, and muscle strength.

Imaging Tests

• MRI of the brain and spine (gold standard)

• CT scan (often used initially in emergencies)

MRI helps determine tumor size, location, and whether it has spread through the CSF.

Lumbar Puncture (Spinal Tap)

A spinal fluid sample is analyzed to detect cancer cells, helping determine the disease stage.

Biopsy and Tumor Resection

Surgical removal of the tumor provides tissue for:

• Histological examination

• Molecular and genetic testing

~Staging of Medulloblastoma

Medulloblastoma is staged based on extent of spread, not tumor size alone:

• M0 – No spread

• M1 – Cancer cells in CSF

• M2 – Spread to brain

• M3 – Spread to spinal cord

• M4 – Spread outside the CNS (very rare)

Staging plays a critical role in treatment planning and prognosis.

~Treatment Options for Medulloblastoma

Treatment typically involves a multimodal approach, combining surgery, radiation therapy, and chemotherapy.

1. Surgery

The primary goal is maximum safe tumor removal. Complete resection improves survival but must avoid damage to vital brain structures.

In some cases, hydrocephalus is treated with:

• Ventriculoperitoneal (VP) shunt

• Endoscopic third ventriculostomy (ETV)

2. Radiation Therapy

Radiation therapy targets remaining cancer cells after surgery.

• Craniospinal irradiation (CSI) is commonly used

• Lower doses may be used in low-risk patients

• Radiation is often delayed or minimized in children under 3 due to developmental risks

3. Chemotherapy

Chemotherapy is used:

• Alongside radiation

• To reduce radiation doses

• As primary treatment in infants

Common chemotherapy drugs include:

• Cisplatin

• Vincristine

• Cyclophosphamide

• Lomustine

~Side Effects and Long-Term Complications

While survival rates have improved, medulloblastoma treatment can cause long-term effects, especially in children.

Possible Long-Term Effects

• Cognitive and learning difficulties

• Hearing loss

• Hormonal imbalances

• Growth delays

• Secondary cancers (rare)

Ongoing rehabilitation and long-term follow-up care are essential to address these challenges.

~Prognosis and Survival Rates

Prognosis depends on several factors:

• Age at diagnosis

• Molecular subtype

• Extent of tumor removal

• Spread at diagnosis

General Survival Statistics

• Low-risk patients: 80–90% 5-year survival

• High-risk patients: 60–70% 5-year survival

• WNT subtype: Best outcomes

• Group 3 subtype: Poorest prognosis

Early diagnosis and advances in precision medicine continue to improve outcomes.

~Medulloblastoma in Adults

Adult medulloblastoma is rare and differs from pediatric cases.

• More commonly SHH-activated

• Often diagnosed later

• Treatment is similar but adjusted for tolerance

Adults may experience fewer cognitive side effects but often face longer recovery periods.

~Current Research and Emerging Therapies

Ongoing research aims to improve survival while reducing treatment toxicity.

Promising Areas of Research

• Targeted therapies for SHH and WNT pathways

• Immunotherapy and vaccine-based treatments

• Proton beam therapy to reduce radiation damage

• Molecular risk stratification

Clinical trials are playing a critical role in shaping the future of medulloblastoma treatment.

~Living With and Beyond Medulloblastoma

Survivorship care focuses on:

• Regular MRI monitoring

• Neurocognitive assessments

• Psychological support

• Physical and occupational therapy

Support groups and counseling can help patients and families navigate emotional and social challenges.

~Frequently Asked Questions (FAQs)

Is medulloblastoma curable?

Yes, many cases are treatable, especially when diagnosed early and classified as low-risk.

Can medulloblastoma recur?

Recurrence is possible, particularly within the first few years after treatment.

Is medulloblastoma hereditary?

Most cases are not inherited, though rare genetic syndromes increase risk.

~Conclusion

Medulloblastoma is a serious and aggressive brain tumor, but modern medical advances have dramatically improved outcomes. Early diagnosis, precise molecular classification, and personalized treatment strategies now allow many patients—especially children—to survive and lead fulfilling lives.

Ongoing research continues to push the boundaries of treatment, offering hope for even better survival rates and quality of life in the future.